New Oral Anticoagulants Markets (amazon) (shopzilla)


(PRWEB) June 26, 2013

New Oral Anticoagulants Markets

TriMarkPublications.com cites in its newly published New Oral Anticoagulants Markets report that the global anticoagulants market will spike to over $ 24 billion by 2019.

Anticoagulants decrease the ability of the blood to create harmful blood clots that can ultimately lead to a heart attack or stroke. Although sometimes referred to as blood thinners, they do not actually thin the blood and only help prevent the formation of new blood clots.

Anticoagulants can be categorized into five main modalities: low molecular weight heparins (LMWHs), herapins, warfarin, direct thrombin inhibitors (DTIs) and factor Xa inhibitors. For more than 50 years and until recently, the only oral anticoagulants were vitamin K antagonists such as warfarin. Pradaxa (dabigatran), Xarelto (rivaroxaban), Eliquis (apixaban) and other new oral anticoagulants have several advantages over warfarin, including no periodical laboratory monitoring and more predictable effects with fixed doses.

The U.S. anticoagulants market, which encompasses over 60% of the global market for anticoagulants, will grow from $ 7.06 billion in 2012 to $ 15.32 billion in 2019 as it shifts from being monopolized by a single injectable anticoagulant, warfarin, to once-daily oral anticoagulants.

New Oral Anticoagulants Markets provides a thorough overview of these and other new oral anticoagulants, their approved indications, drug profiles, pharmacokinetic parameters and the respective areas of market growth.

The report also examines companies manufacturing anticoagulant equipment and supplies in the world. Companies covered include: Akers, Anthera, ARYx, AstraZeneca, Boehringer Ingelheim, Cipla, Daiichi Sankyo, Eisai, Eli Lilly, Genentech, GlaxoSmithKline, Medicines Company, Medicure, Merck, Novartis, Ortho-McNeil, Pfizer, Pharmion, Portola and Sanofi. Detailed charts with sales forecasts and marketshare data are included.

New Oral Anticoagulants Markets Table of Contents:

1. Introduction

1.1 Scope of this Report

1.2 Methodology

1.3 Executive Summary

2. An Overview of Anticoagulants

2.1 Scope of this Chapter

2.1.1 Unmet Medical Needs with Existing Anticoagulants

2.1.2 Pharmacology of Injectable Anticoagulants

2.1.3 Marketed and Registered Drugs for Anticoagulation and Related Disorders

2.2 Oral Anticoagulants

2.2.1 Potential Limitations of New Oral Anticoagulants

2.2.2 Desired Attributes of Anticoagulants

2.2.3 Comparison of New Anticoagulants

2.2.4 Bleed Rates of New Anticoagulants

3. Selected Oral Anticoagulants

3.1 Warfarin

3.1.1 Warfarins Place in Clinical Therapy

3.1.2 Drug Interaction with Warfarin

3.1.3 Warfarins Interactions with Food

3.1.4 Interactions of Warfarin with Dietary Vitamin K

3.2 Dabigatran (Pradaxa)

3.2.1 Use of Dabigatran in Particular Situations

3.2.2 Measuring the Anticoagulant Effect of Dabigatran

3.2.3 Activated Partial Thromboplastin Time (aPTT)

3.2.4 Thrombin Time (TT) and Hemoclot

3.2.5 Ecarin Clotting Time (ECT)

3.2.6 Prothrombin Time (PT) and INR

3.2.7 Measures for Overdose

3.2.8 Management of Bleeding Complications

3.2.9 For Patients Undergoing Surgical Intervention

3.2.10 For Dental Interventions

3.2.11 For Spinal Anesthesia/Epidural Anesthesia/Lumbar Puncture

3.2.12 For Patients with Acute Coronary Syndrome (ACS)

3.2.13 Cardioversion in Dabigatran Treated Patients

3.2.14 For Patients with Stroke

3.2.15 Dabigatran after Ischemic Stroke

3.2.16 Strengths and Weaknesses of Dabigatran

3.2.16.1 Strengths of Dabigatran in Metabolism, Pharmacokinetics and Pharmacodynamics

3.2.16.2 Weaknesses of Dabigatran in Metabolism, Pharmacokinetics and Pharmacodynamics

3.2.16.3 Strengths of Dabigatran in Laboratory Monitoring

3.2.16.4 Weaknesses of Dabigatran in Laboratory Monitoring

3.2.16.5 Strengths of Dabigatran in Clinical Efficacy

3.2.16.6 Weaknesses of Dabigatran in Clinical Efficacy

3.2.16.7 Strengths of Dabigatran in Controlling Bleeding

3.2.17 Comparison of Dabigatran and Rivaroxaban in Sites of Action

3.3 Rivaroxaban (Xarelto)

3.3.1 Dosage and Administration

3.3.2 Risk of Stroke after Discontinuation in Non-Valvular Atrial Fibrillation

3.3.3 Risk of Bleeding

3.3.4 Bleeding Events in ROCKET AF Trial

3.3.5 Bleeding Events in RECORD Trial

3.3.6 Overdosage

3.3.7 Mechanism of Action

3.3.8 Comparable Efficacy of Rivaroxaban

3.3.9 Prophylaxis of Deep Vein Thrombosis

3.4 Eliquis (Apixaban)

3.4.1 AVERROES Results

3.5 Edoxaban

3.6 Betrixaban

3.7 Pipeline Agents

3.8 Comparison of Oral Anticoagulants

3.9 Heparins

3.10 Dalteparin (Fragmin)

3.11 Enoxaparin (Lovenox)

3.11.1 Indications and Usage

3.11.2 Percutaneous Coronary Revascularization Procedures

3.11.3 Use of Lovenox with Concomitant Medical Conditions

3.11.3.1 Thrombocytopenia

3.11.3.2 Interchangeability with Other Heparins

3.11.3.3 Pregnant Women with Mechanical Prosthetic Heart Valves

3.11.3.4 Laboratory Tests

3.11.3.5 Pharmacodynamics

3.11.3.6 Pharmacokinetics

3.12 Fondaparinux (Arixtra)

3.13 Tinzaparin (Innohep)

3.14 Semuloparin Sodium (AVE5026)

3.15 Idrabiotaparinux

3.16 Otamixaban

3.17 RB006

3.18 Reversal Agents and Antidotes

3.18.1 Vitamin K

3.18.2 Recombinant Factor VIIa

3.18.3 Prothrombin Complex Concentrates

4. A Brief Overview of Antiplatelets

4.1 Overview of this Chapter

4.1.1 Differences between Antiplatelets and Anticoagulants

4.1.2 Need for Antiplatelets

4.1.3 Side Effects of Antiplatelets

4.1.4 Choosing an Antiplatelet

4.1.5 Role of Platelets in Thrombosis

4.1.6 Inhibitors of Platelet Adhesion

4.1.7 Inhibitors of Platelet Activation

4.1.7.1 Inhibitors of TXA2 Pathway

4.1.7.2 Inhibitors of P2Y12

4.1.7.3 PAR-1 Inhibitors

4.1.7.4 Phosphodiesterase Inhibitors

4.2 Antiplatelet Drugs

4.2.1 Aspirin

4.2.2 Aggrenox

4.2.3 Ticagrelor (Brilinta)

4.2.4 Clopidogrel (Plavix)

4.2.4.1 Indications and Usage

4.2.4.2 General Risk of Bleeding

4.2.5 Effient (Prasugrel)

5. Coagulation Assays

5.1 Clotting Assays

5.1.1 Chromogenic Methods

5.1.2 Prothrombin Time

5.1.3 Activated Partial Thromboplastin Time

5.1.4 Thrombin Time

5.1.5 Fibrinogen (Clauss Method)

5.1.6 Derived Fibrinogen

5.1.7 Antithrombin

5.1.8 Protein C

5.1.9 Protein S

5.1.10 Lupus Anticoagulants

5.1.11 ProC Global Assay and APC Resistance (APCR)

5.2 Influence of New Anticoagulants on Coagulation Assays

6. Disease Conditions Targeted by Anticoagulants

6.1 Cardiovascular Diseases

6.1.1 Stroke

6.1.2 Ischemic Stroke

6.1.3 Hemorragic Stroke

6.1.4 Subarachnoid Hemorrage

6.1.5 Global Incidence and Prevalence of Stroke

6.1.6 Incidence of Stroke in the U.S.

6.1.7 Mortality from Heart Disease and Stroke i

Related Anti Aging Supplements Press Releases

Related Blogs

    True-Dose Takes Pet Supply Markets Internationally (amazon) (shopzilla)


    St. Louis, MO (PRWEB) April 30, 2013

    True-Dose is proud to announce record sales for its all-natural pet supplements in international markets. This year, True-Dose has secured their position as the supplement of choice for pet parents in Japan, Korea and Hong Kong.

    Herbal medicine has long been incorporated into healthcare throughout Asia, and pet parents seeking all-natural solutions for their pets prefer natural products as well. Markets in Asia have responded well to True-Dose human grade supplements made from all natural ingredients. The True-dose product line includes vitamins, minerals and herbal supplements.

    Because the number of pets in Asia far outnumbers household pets in the United States, True-Dose sees the Asian markets as a great opportunity to expand its presence internationally and to provide high-quality products to customers worldwide. Statistics show that International pet markets are growing rapidly.

    Euromonitor International published several statistics relative to the pet product market Asia. In Japan, with more than 21 million pets for instance, the number of household pets is now greater than the number of children under the age of 14. It was was noted that Korea was one of the fastest growing pet markets over the last three years, growing 8% in value last year alone. The increased interest in pets also is growing In Hong Kong, with the most popular pet care trends focusing on anti-aging products and pet dietary supplements.

    The pet market in Asia is booming and True-Dose provides the American-made quality difference they need, said True-Dose founder Joe Wayman. Asia has a much higher population of smaller breed pets, and it is difficult for these smaller breed companion animals to consume tablets. Accuracy in dosing and convenient administration is very important to pet parents in Asia. It is easy for small breeds to consume True-Dose daily on their food, and the results are evident after just a few days.

    About True-Dose

    True Dose, headquartered in St. Louis, MO, uses a patented system to produce high-quality natural supplements for canines and felines. Their products address joint care, skin and coat care, calming, and dental care. True-Dose supplements are manufactured in human pharmaceutical facilities, following the same strict testing and quality standards mandated by the FDA for state-of-the-art human pharmaceutical product manufacturing. Their raw ingredients are certified and tested to ensure they meet strict quality standards. The founders of True-Dose have long had the goal of providing human-quality, pharmaceutical-grade products to our four-legged friends.

    All of our products are sourced and tested to human standards and manufactured in a pharmaceutical facility, said Joe Wayman, Founder and President of True-Dose. Our goal with responsible sourcing is to ensure the same quality for pets that we expect for ourselves. Pets have now established themselves as part of the family, often considered to be like one of the children. True-Dose has a mission of better companion animal health with the understanding that pets have a tremendous impact on both the mental and physical health of humans.

    True Dose ensures quality ingredients as well as accuracy and ease of dosage. True Dose products have been clinically proven to have a faster absorption rate and higher peak serum/blood concentrations than tablets and chewables. The absorption rate was validated in a head-to-head crossover clinical study conducted by the Oklahoma State University Veterinary Science and Research Departments.

    To find out more about Euromonitor statistics visit: http://www.euromonitor.com/pet-products-in-japan/report








    Related Blogs

      Top Selling Non-Surgical Facelift from Liberty Health Network Capitalizes on Success on Amazon.com by Expanding Into New International Markets. Follow LHN @GoLHN (amazon) (shopzilla)


      Tampa Bay, FL (PRWEB) October 26, 2012

      After experiencing over 12 consecutive months of double-digit sales growth of their best selling Beau Visage Non Surgical Face Lift lineup, Liberty Health Network, LLC (LHN) announces a massive product distribution expansion .

      While LHN has experienced massive success in the US, the company knew that there is a substantial International market for premium Anti Aging products.

      “Why should American women and men be the only ones to experience the age reversing effects of our Beau Visage Facelift Without Surgery products?” Quipped LHN Chief Operating Officer Russell Bly. “Seriously, the products work great. We have an insignificantly low returned product rate. Our customers love the products. There’s really no reason not to expand our distribution.” Bly said.

      Effective immediately, LHN will begin shipping Beau Visage products on Amazon.Com to the following countries:

      American Samoa, Guam, Marshall Islands, Federated States of Micronesia, Northern Mariana Islands, Palau, Puerto Rico, Virgin Islands (U.S.), APO/FPO, Albania, Andorra, Austria, Belarus, Belgium, Bosnia-Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Faroe Islands, Finland, France, Georgia, Germany, Gibraltar, Greece, Greenland, Guernsey, Holy See, Hungary, Iceland, Ireland, Israel, Isle Of Man, Italy, Jan Mayen Is., Jersey, Kosovo, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Monaco, Montenegro, the Netherlands, Norway, Poland, Portugal, Romania, Russia, San Marino, Republic of Serbia, Slovakia, Slovenia, Spain, Svalbard, Sweden, Switzerland, Turkey, Ukraine, United Kingdom and Yugoslavia Asia

      Related Blogs

        Subscribe By Email for Weekly Updates.